Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (April 2012)
37 slides from Fluoropharma Medical's investor presentation, Apr 16, 2012
Slide 1: Enabling Personalized Medicine by Making the Invisible, Visible
Flue@n@niea. << @Phakma Enabling Personalized Medicine by Making the Invisible, Visible.
Slide 2: Forward-Looking Statements
Fluoro d-Looking Statements Pharma This presentation contains “forward-looking statements” within the meaning of the Seourities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by the
Slide 3: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Fluoro Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE HEART IMAGING PROGRAMS CLINICAL BENEFIT PATIENT MANAGEMENT * Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital * Imaging drugs for diagnostic testing + BFPET => Myocardial perfusion im
Slide 4: Investment Highlights
Fluoro it Highlights Pharma Proprietary products that support new technologies for personalized medicine + Next generation / first.in-class diagnostic imaging + Helps determine the course of cardiac treatment Two Phase Il-ready products with short study timelines, both directed to very large markets
Slide 5: Molecular Imaging Value Chain
Molecular Imagin; Pharmaceutic Distribution PETNET Phillips Scann Developmer Multiple players in each value chain Fluoro Pharma www.FluoroPharma.com
Slide 6: Large, Growing Market for Imaging Agents
Fluoro Large, Growing Market for Imaging Agents Pharma y ; Imaging Drug Market Global market expected to exceed $15 billion by 2015 Worldwide Sales Forecast * Fueled by need for personalized medicine , ara 20 $158 Total * Additional drivers include: 2 + Growing volume of diagnostic examinations $78
Slide 7: Big Step in Healthcare
Fluoro Big Step in Healthcare MEDICINE TODAY One treatment fits all - ad jarma still a guessing game www. FluoroPharma.com
Slide 8: Medicine Tomorrow Must Be Personalized
Diagnosis Pharma MEDICINE TOMORROW must be personalized Right Treatment for the Right Patient at the Right Time for the Right Outcome gy Before you can see it, Before the patient feels it, We can identify it Personalized medicine begins with the right diagnosis www. FluoroPharma.com
Slide 9: FluoroPharma Enables Personalized Diagnosis
ae FluoroPharma Enables Personalized Diagnosis Pharma Imaging provides non-invasive tools with immediate personalized recommendations for treatment * Allows direct visual evaluation of (atetiols q disease on a chemical level + Measures the efficacy of treatment Utasound singe bubble + Tracks respons
Slide 10: Market Drivers for New PET Products
Fluoro Market Drivers for New PET Product ~ Pharma Low capacity Comprehensive adoption of early utilization diagnosis will improve utilization of technology + At capacity, more patients could be diagnosed earlier leading to better patient ‘outcomes 1,740) + Earlier diagnosis benefits the health syst
Slide 11: PET Imaging Roots are in Oncology
Fluoro PET Imaging Roots are in Oncology = Pharma PET procedures by disease area (by amount tracer) 2500 2000 Cardiology 1500 and neurology remain strong 1000 growth opportunities 500 A = = 2004 2005 2006 2007 2008 2008 Year @ Oncology Ml Neurology Ml Cardiology Source Frost Suliven 2008 www. Fluoro
Slide 12: Cardiovascular Disease is the Next Big Opportunity
cular Disease is the Next Big Opportunity Total diagnostic radiopharmaceutical agents market: procedure volume forecasts by imaging procedure (U.S.) - a switch to PET as, Procedure (millions) 219 / 213 20.1 20.4 AD 189 {i Z 2008 2009 2005 2006 2007 Year ME SPECT(Other) Ill SPECT (Cardiac) Ml PET 200
Slide 13: Cardio Diagnostics
Fluoro Cardio Diagnostics Pharma Cardiovascular Diagnost PET Molecular Imaging + Lin-3 adults have some form of CV + Superior image quality disease + Large rapidly growing imaging platform + >10 million CV nuclear scans (MPI) in 2009* + Increasing demand for PET technology + $403 billion: fully burd
Slide 14: Unmet Need for Better Imaging Methods
Fluoro Unmet Need for Better Imaging Methods. = Pharma FDA Warning in 2007 . fibrosis for contrast agents 7 =m nr FDA Warning in 2007 ANATOMICAL > rai IMAGING + Deaths and serious cardiopulmonary reactions arising , from marketed products AHA 2007 Statement. + CTAis reasonable for assessment of CAD
Slide 15: Making the Invisible, Visible
Fluoro Making the Invisible, Visible —— Pharma CardioPET VasoPET Z ‘metabolic insufficiency | inflamed plaques | + For use in combination with + Modified fatty acid (MFA) with an | + Avidly taken up by inflammatory stress-testing in patients with internal block to prevent cells and rapidly dividing
Slide 16: BFPET Clinical Use
Fluoro BFPET Clinical Use Pharma MYOCARDIAL PERFUSION IMAGING + Evaluate patients with known or suspected CAD for perfusion, wall motion and ejection fraction *+ Evaluate CAD in patients that are able to exercise CURRENT DIAGNOSTIC TEST + Perfusion imaging with SPECT tracers (MIBI, TI-201) or Rb-82
Slide 17: BFPET Phase I Trial Findings
BFPET Phase | Trial Findings +12 heathy volunteers ages 20:85 4 + No adverse event : + No einiealysignicant changes noted : in follow-up clinical and laboratory testing . Fluoro - Pharma Rapid extraction from blood Stable heart uptake over time High target to background ratios Convenient imaging win
Slide 18: The BFPET Opportunity
Fluoro The BFPET Opportunity — Pharma Projected BFPET Scans ‘miLLioNs os Assumptions o7 Est. 5" Year Revenue 36 $209 million 0s Market Est. MktSize Est. Share os 03 Myocardial perfusion 0 mnie os 02 on Year Year3 Years Peak procedure volume ~0.8 mil. www. FluoroPharma.com
Slide 19: CardioPET Clinical Use
Fluoro CardioPET Clinical Use Pharma CARDIAC VIABILITY ASSESSMENT + Identify patients that will benefit from PCI or revascularization and guide intervention + Evaluate CAD in patients that cannot exercise CURRENT TREATMENT + Invasive coronary angiography CLINICAL NEED + 1.3 million diagnostic angiog
Slide 20: CardioPET Phase I Results
CardioPET Phase | Results Fatty acid analog that detects regions of metabolic insufficiency PHASE | TRIAL COMPLETED (15 NHV and 6 CAD patients) + CardioPET is safe with no AEs detected * Clinical findings consistent with MPI SPECT + Quality of CardioP ET images substantially superior to MPI SPEct 15
Slide 21: The CardioPET Opportunity
Fluoro The CardioPET Opportunity = Pharma MiLuoNs 09 Est. 5 Year Revenue 08 $230 million O7 . 06 Market Est MitSize Est-Share CAD diagnosis at rest 2.5 million 15% 04 03 Cardiac viability assessment ze mition 8 02 Myocardial perfusion 45 wiilon en me imaging — | a Peak procedure volume ~1 million ww
Slide 22: VasoPET Indications and Clinical Use
Fluoro VasoPET Indications and Clinical Use Pharma EVALUATION OF + Patients with acute cardiac event or stroke (risk of recurring event) + Therapy following acute cardiac event or stroke (e.g., Plavix, lipid therapy, new treatments) CURRENT DIAGNOSTIC PRACTICE + Clinical symptoms; several imaging ag
Slide 23: Detection Of Inflamed Atherosclerotic Plaque
Fluoro - Detection Of Inflamed Atherosclerotic Plaque Pharma WHY INFLAMMATION IMAGING? * Diagnosis before symptoms occur * Crucial role at all stages of atherosclerosis, + May aid drug development DEVELOPMENT STATUS + Preclinical testing completed * IND preparation ongoing + Plan to initiate Phase |
Slide 24: The VasoPET Opportunity
Fluoro The VasoPET Opportunity = Pharma Est. 5" Year Revenue 05 $213 milion . 04 Market Est. MktSize Est. Share Screening for 03 atherosclerosis, SP.lon 8% Folk hi ee lowup afterheart 9.9 million 10% attack Follow-up after stroke 0.8 million 10% ou J 2 Peak procedure volume ~0.6 million www. FluoroP
Slide 25: Targets Greatest Areas for Cost Reduction
Fluoro Targets Greatest Areas for Cost Reduction Pharma Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise enabling r driven medicine offer greatest route to reducing the overalll costs of healthcare Medical Concerns that Present
Slide 26: Experienced Management Team and Advisors
Experienced Management Team and Advisors Fluoro Pharma H. Wiliam Strauss, MD Daniel Berman, MO Peter Cont, MD, PRO lazer Edelman, MD, PRD MD Thijs Spoor President, CEO indus GE Healthcare + Degrees in nuclear pharmacy (Toronto) and finance (Columbia) David R. Elmaleh, PhO Founder, Chairman + Asso ci
Slide 27: Growth Strategy / Near-Term Milestones
Growth Strategy / Near-Term Milestones Fluoro Pharma Capitalize on multiple cardiovascular molecular imaging agents for PET * Cardiac viability assessment + Myocardial perfusion imaging * Inflamed atherosclerotic plaque imaging Address unmet needs in cardiovascular diagnostics by providing + Diagnos
Slide 28: Fluo.
Fluo. aciaelakiich
Slide 29: The cycle of classic medicine is reactive medical care
Fluoro The cycle of classic medicine is reactive medical care = Pharma Reactive Medical Care Switch Dr Switch Drug Select Drug Disease Severity Time Diagnose Disease; Treat Symptoms; Costly, Trial and Error Treatment Personalized Median Coaltion Abrahams Presentation www. FluoroPharma.com
Slide 30: Shifting to outcomes focused personalized treatments increases efficiency
Fluoro Shifting to outcomes focused personalized treatments increases efficiency = Pharma Efficient Medical Care Disease Severity Health Management; Molecular Screening; Early Detection; Rapid Effective Treatment; Improved Quality of Care Personalized Median Coaltion, Abrahams Presentation www. Fluo
Slide 31: Cardiovascular Disease
Fluoro Cardiovascular Disease Pharma Reactive Medical Care Switch Dr Switch Drug Select Drug Disease Severity Time Diagnose Disease; Treat Symptoms; Costly, Trial and Error Treatment Personalized Median Coaltion Abrahams Presentation www. FluoroPharma.com
Slide 32: Cardiovascular Disease
Fluoro Cardiovascular Disease ath ERK KEY FACTS - US AND WW WHO: “Neglected Global Epidemic” + 16.7M deaths WW: 4/3 of all deaths, 78% from He Myecaral low / middle income countries. + 1/3 of deaths in China, ¥ in Europe + 2.4M deaths US: top cause (38.5%) Pharma infarction (Ml) KEY UNMET NEEDS * CA
Slide 33: Vulnerable Plaque Imaging
Vulnerable PI = Fn | Individual Plaques ‘Antony 0 0 a Plaque Imaging www.FluoroPharma.com
Slide 34: AD Statistics
Fluoro AD Statistics Pharma AD Pathological Hallmarks * 4th leading cause of death after Beta-amyloid Plaques CHD) cancer and stroke: Amyloid Precursor Protein > plaques + 25M people estimated to have AD globally (2000). + Incidence - 4.5M globally (2000). eee Neurofibrillary Tangles + By 2030, 63M
Slide 35: Regulatory Strategy - CardioPET
Fluoro Regulatory Strategy -CardioPET Pharma US FDA requirements for NDA: safety and efficacy Phase la Safety, dosimetry and pharmacokinetics; imaging protocol in (Completed) healthy volunteers (15 NHV); single center Phase Ib Safety, pharmacokinetics and comparison to MPI in small (Completed) numbe
Slide 36: Outcomes partnerships drive clinical trial endpoints
Fluorc Outcomes partnerships drive clinical trial endpoints _— Pharma Economic pressures PAST FUTURE Fragmen- BS SF S 2 So y 5 2 Integrated, IE systems of systems ol Decisions by individual stakeholders care care — delivery = __ Decisions by advanced stakeholder net freee AW) Aligned () Conventional
Slide 37: Thank you
Thank you for listening!
FluoroPharma Medical — Investor Presentation (April 2012) on 6ix